Ovarian Follicles: Anatomy, Function, and Disorders

Ovarian follicles are the functional units of the ovary, each one a tiny fluid-filled sac that houses and nurtures an immature egg cell. They do far more than store eggs: follicles produce hormones, respond to signals from the brain, and communicate with each other through an elaborate chemical conversation that determines which egg gets released each month and which do not. Understanding how follicles form, grow, and sometimes go wrong touches on everything from basic fertility to conditions like polycystic ovary syndrome and premature menopause.

What a Follicle Actually Looks Like

A follicle is not just an egg floating in space. It is a structured compartment with distinct layers, each serving a purpose. At the center sits the oocyte, the immature egg cell. Surrounding it is a layer of granulosa cells that directly support and feed the oocyte. Outside the granulosa layer sits a shell of theca cells, which supply blood vessels and produce key hormones. A basement membrane separates the granulosa cells from the theca layer, and the composition of that membrane changes as the follicle matures. In the earliest primordial follicles, this membrane is made up of collagen IV and laminin. As follicles grow into primary and secondary stages, fibronectin joins the mix, adding structural complexity to the wall.¹

Once a follicle develops beyond the early stages, a fluid-filled cavity called the antrum forms inside it. This antral fluid is not just padding. It originates from blood plasma and secretions from both granulosa and theca cells, driven by an osmotic gradient created by molecules like hyaluronan and versican. The fluid acts as a reservoir of signaling molecules, hormones, and nutrients that influence the oocyte’s maturation and provide a window into what is happening inside the follicle.² Clinicians sometimes analyze follicular fluid during fertility procedures because its composition reflects the health of the follicle’s internal environment.

From Dormant to Dominant

At birth, the ovaries contain a finite pool of primordial follicles, each one tiny, dormant, and waiting for a signal to start growing. This pool is the lifetime supply. No new follicles are created after birth, so the entire reproductive timeline depends on how and when these dormant follicles are activated.

Follicle development, called folliculogenesis, moves through a defined series of stages. A primordial follicle activates and becomes a primary follicle, then a secondary follicle, and eventually an antral follicle with its fluid-filled cavity. Each stage involves structural and functional changes within the follicle that prepare the oocyte for eventual release.³ The early stages of this process are largely independent of pituitary hormones. The follicle grows because of local signals within the ovary itself. But there is a critical turning point: the transition from the preantral to the antral stage is when follicles become dependent on follicle-stimulating hormone from the pituitary gland. From that point on, FSH drives the process, and follicles that do not receive enough FSH support will die off.⁴

Out of the cohort of follicles that begin growing each cycle, typically only one achieves “dominance” in humans. That dominant follicle grows faster, produces more estrogen, and suppresses the growth of its competitors. The rest undergo atresia, a process of programmed degeneration. This selection mechanism ensures that, in most cycles, only a single mature egg is released.

How Two Cell Types Cooperate to Make Estrogen

Hormone production inside a follicle requires teamwork between its two main cell types, and the division of labor is strict. Theca cells on the outer layer respond to luteinizing hormone by producing androgens. The gene responsible for a critical step in androgen production is expressed only in theca cells, not in granulosa cells.⁵ Those androgens then pass inward to the granulosa cells, which convert them into estrogen using an enzyme called aromatase. This enzyme is activated by FSH. So estrogen production requires both LH acting on theca cells and FSH acting on granulosa cells working in tandem.⁶

This arrangement matters clinically because disruptions to either cell type, or to the hormone signals they depend on, can throw the whole system off. If theca cells overproduce androgens (as in polycystic ovary syndrome), or if granulosa cells cannot aromatize those androgens efficiently, the balance shifts in ways that affect both hormone levels and fertility.

Another hormone with a gatekeeper role is anti-Müllerian hormone, produced by granulosa cells of growing follicles. AMH puts the brakes on follicle activation. In mouse ovaries treated with AMH, about 40% fewer primordial follicles began growing compared to untreated controls.⁷ This makes AMH a kind of conservation officer for the ovarian reserve: by limiting how many follicles leave the dormant pool at any one time, it helps ensure the supply lasts throughout reproductive life. AMH levels in blood are now routinely used in fertility clinics as a proxy for ovarian reserve.

The Egg Itself Runs the Show

For a long time, scientists thought of the oocyte as a passive passenger that granulosa cells nursed along. That picture has been upended. The oocyte actively directs its own development by secreting growth factors that tell granulosa and theca cells what to do. Two of the most important are GDF-9 and BMP-15, both members of a large family of signaling proteins. These factors promote granulosa cell growth and differentiation, regulate steroid hormone production, and influence how the follicle matures at every stage from the primordial-to-primary transition all the way through ovulation.⁸

Genetic studies in mice have confirmed just how essential these signals are. When GDF-9 is knocked out, follicle development stalls at an early stage, and the animals are infertile.⁹ GDF-9 and BMP-15 can act as individual molecules or pair up as a combined molecule that is even more potent. They boost processes that prepare the follicle for ovulation, including increasing the expression of receptors for LH on granulosa cells, which is the final step needed for the ovulatory trigger to work.¹⁰ The emerging view is that the egg is not simply being prepared for release; it is actively orchestrating the follicle’s transformation around itself.

What Happens at Ovulation and Afterward

Ovulation is one of the more dramatic events in normal human physiology. The wall of the dominant follicle thins, weakens, and ruptures, releasing the mature egg. Recent research has mapped the molecular programs at work in different regions of the follicle wall during this process. The side of the follicle destined to rupture shows increased activity in genes related to oxidative stress, tissue remodeling, and hormone signaling, while the opposite side is molecularly distinct. Oxidative stress and related cell-death pathways appear to help drive the thinning of the wall at the rupture point.¹¹ It is a controlled demolition: too little wall breakdown and the egg stays trapped; too much and the process becomes destructive.

After the egg exits, the emptied follicle does not just collapse. It transforms into a completely different structure called the corpus luteum, a temporary endocrine gland whose sole purpose is producing progesterone to support a potential pregnancy. Granulosa cells become large luteal cells with a high baseline output of progesterone, while theca cells become small luteal cells that ramp up progesterone production in response to LH.¹² Blood vessels rapidly invade the new structure, immune cells move in, and the whole thing undergoes intense remodeling.¹³ If pregnancy does not occur, the corpus luteum degenerates after about two weeks, progesterone drops, and menstruation follows. If implantation happens, signals from the embryo keep the corpus luteum alive until the placenta takes over progesterone production.

Why Most Follicles Never Make It

The numbers here are striking. A person born with ovaries starts with roughly one to two million primordial follicles. By puberty, that number has already dropped to a few hundred thousand, and over an entire reproductive lifetime only about 400 to 500 will ever ovulate. The vast majority die through atresia, a process of follicle degeneration that can happen at any stage of development.

Atresia is not random cell death. It is regulated by specific molecular pathways. The most studied is apoptosis, or programmed cell death, in granulosa cells. As a follicle becomes atretic, the proportion of granulosa cells undergoing apoptosis rises sharply. Estrogen and insulin-like growth factor appear to have protective roles: follicles with higher levels of these molecules tend to be healthier, while declining levels are associated with the shift toward atresia.¹⁴ More recently, researchers have found that atresia also involves autophagy (a form of cellular self-digestion) and ferroptosis (a type of cell death triggered by iron-dependent damage to cell membranes).¹⁵ One pathway that links these processes involves the transcription factor FOXO1, which can directly activate pro-death genes in granulosa cells and tip a follicle toward degeneration.¹⁶

Atresia is not a defect. It is a quality-control mechanism. By eliminating follicles that received inadequate hormonal support or accumulated damage, the ovary increases the chances that the follicle ultimately selected for ovulation contains a healthy, competent egg. The process becomes a problem only when it accelerates beyond normal rates, as happens in premature ovarian insufficiency.

Polycystic Ovary Syndrome and Stalled Follicles

Polycystic ovary syndrome is the most common endocrine disorder affecting people of reproductive age, and its core follicle problem is straightforward: too many follicles start growing, but none of them finishes. On ultrasound, this shows up as a ring of small antral follicles around the ovary’s periphery, sometimes described as a “string of pearls.” The follicles stall at an intermediate size and fail to reach dominance, so ovulation does not happen regularly or at all.

The hormonal driver behind this is excess androgen production. Elevated androgens disrupt the normal balance of folliculogenesis and lead to follicular arrest.¹⁷ Insulin resistance amplifies the problem: high insulin levels stimulate theca cells to produce even more androgens, creating a feedback loop that worsens both the hormonal imbalance and the metabolic dysfunction. Disruptions to the same paracrine signals discussed earlier, including AMH, BMP-15, and GDF-9, also contribute to the arrested development of follicles in PCOS.

Because AMH is produced by the granulosa cells of growing follicles, and PCOS ovaries contain an unusually large number of small growing follicles, AMH levels tend to be elevated in people with the condition. This makes AMH measurement useful not only for assessing ovarian reserve in general but also as a diagnostic clue for PCOS, though it is not yet part of the formal diagnostic criteria in all clinical guidelines.

Premature Ovarian Insufficiency

Premature ovarian insufficiency, or POI, is defined as the loss of ovarian function before age 40. It manifests as irregular or absent periods, low estrogen, and elevated FSH, essentially the hormonal profile of menopause but arriving years or decades too early. The follicle pool either started too small, depleted too quickly, or stopped responding to hormonal signals.¹⁸

Most cases have no identified cause. Genetic factors account for some, including chromosomal abnormalities and mutations in genes involved in folliculogenesis. Autoimmune attack on the ovaries is estimated to account for somewhere between 4% and 30% of cases, a wide range that reflects how difficult autoimmune POI is to confirm without a tissue biopsy. Chemotherapy and pelvic radiation can also destroy follicles directly, which is why fertility preservation is discussed before cancer treatment in young patients whenever possible. POI does not always mean complete and permanent absence of follicles: some people with POI still have intermittent follicular activity and occasional ovulation, which is why the older term “premature ovarian failure” has fallen out of favor.

How Aging Changes Follicle Quality and Quantity

The decline in follicle numbers is gradual for most of reproductive life, then accelerates sharply around the late thirties. But the number of remaining follicles is only part of the story. Oocyte quality also declines with age, contributing to lower fertility, higher miscarriage rates, and increased chromosomal abnormalities in pregnancies.¹⁹ This dual decline in both quantity and quality is what makes age the single strongest predictor of fertility outcomes in assisted reproduction.²⁰

The mechanisms behind age-related quality decline include accumulated oxidative damage to the oocyte, deterioration of the cellular machinery that segregates chromosomes during cell division, and changes in the surrounding granulosa cells that reduce their supportive capacity. These are not problems you can feel or measure with a simple blood test, which is part of what makes age-related fertility decline frustrating: AMH and antral follicle count can tell you something about how many follicles remain, but they say much less about the competence of the eggs inside those follicles.

Follicles in Fertility Treatment

The entire premise of controlled ovarian stimulation, used in IVF and related procedures, is to override the body’s natural single-follicle selection. By giving exogenous FSH (and sometimes LH), clinicians rescue follicles that would otherwise have died through atresia, encouraging multiple follicles to mature simultaneously.²¹ The goal is to retrieve several mature eggs in a single cycle, improving the odds of producing viable embryos.

How well someone responds to stimulation varies considerably, and genetics plays a role. Variations in the FSH receptor gene influence how sensitive follicles are to the hormone. In one study, people with one particular variant of this receptor had significantly higher clinical pregnancy rates after IVF compared to those with a different variant, and the variant associated with poorer response tended to require higher doses of medication.²² This kind of genetic variability is part of why two people of the same age and similar hormone levels can have very different IVF outcomes.

For people with PCOS or a high antral follicle count, in vitro maturation (IVM) offers an alternative approach. Rather than flooding the ovaries with hormones to push many follicles to full size, IVM involves collecting immature eggs with little or no stimulation and then maturing them in the lab before fertilization. This technique is now classified as nonexperimental and is particularly suited for patients who are at risk of ovarian hyperstimulation syndrome.²³

Growing Follicles Outside the Body

Perhaps the most futuristic frontier in follicle biology is the attempt to grow functional follicles entirely in vitro, from the primordial stage through to a mature, fertilizable egg. This matters most for fertility preservation. A young cancer patient, for example, might have ovarian tissue frozen before chemotherapy. If scientists could later isolate primordial follicles from that tissue and grow them to maturity in the lab, it would eliminate the need for re-transplanting tissue back into the body.

Progress has been real but slow. Transplants of fresh and frozen ovarian tissue have already demonstrated that banked tissue can restore both hormone production and fertility.²⁴ The next step, culturing isolated follicles, has shown that a two-step system using three-dimensional support structures can produce eggs capable of completing their final maturation in about one in five cases.²⁵ That is far from a reliable clinical tool, but it demonstrates the concept. The challenge is that a primordial follicle needs months of continuous growth and perfectly timed hormonal cues to produce a viable egg, and replicating that entire trajectory in a dish remains extraordinarily difficult.

How Follicle Biology Differs Across Species

Much of what we know about follicles comes from studies in mice and rats, but the translation to human ovaries is not always clean. The core machinery is shared: antral follicles grow in response to FSH, ovulation involves enzymatic breakdown of the follicle wall, and the steroid hormone pathways are largely the same across mammals. But embedded in those similarities are differences shaped by each species’ reproductive strategy.²⁶

Rodents, for instance, ovulate multiple eggs per cycle as a norm, while humans almost always ovulate one. The corpus luteum in rodents has a different lifespan and hormonal dependency than in primates. Estrogen’s role in triggering the LH surge that causes ovulation also differs between species. These distinctions matter for anyone interpreting fertility research, because a drug or gene therapy that works beautifully in a mouse ovary may behave differently in a human one. Researchers have increasingly argued that careful cross-species comparison, rather than treating one model as a stand-in for all mammals, yields the most useful insights into how follicles actually work.